3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Burkitt Lymphoma
7
Leukemia, Biphenotypic, Acute
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
3
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Prostatic Neoplasms
1
Pneumonia
1
Neoplasms
1
Neoplasm Metastasis
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, Extranodal NK-T-Cell
1
Lymphohistiocytosis, Hemophagocytic
1
Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hepatectomy
1
Hematologic Neoplasms
1
Drug-Related Side Effects and Adverse Reactions
1
Down Syndrome
1
Brain Neoplasms
1
Blastic Plasmacytoid Dendritic Cell Neoplasm
1
Acute Gout
1
Interventions
venetoclax
28
Rituximab
22
ibrutinib
21
acalabrutinib
21
Cyclophosphamide
20
Specimen Handling
18
obinutuzumab
15
Biopsy
14
fludarabine
13
zanubrutinib
10
pirtobrutinib
10
fludarabine phosphate
9
Magnetic Resonance Spectroscopy
8
Bendamustine Hydrochloride
8
idelalisib
6
Whole-Body Irradiation
6
Mycophenolic Acid
6
Lenalidomide
6
CT-P10
6
ARQ531
6
Cyclosporine
5
Sirolimus
4
Peripheral Blood Stem Cell Transplantation
4
pembrolizumab
3
Vincristine
3
Tacrolimus
3
Prednisone
3
Doxorubicin
3
Disulfides
3
Cyclosporins
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Leukemia, Lymphocytic, Chronic, B-Cell
×
Methylprednisolone
×
90 days
×
Clear all
NCT06970743
2026-05-11
CaDAnCe-303
BeOne Medicines
Phase 3
Recruiting
150 enrolled